Data are available from the Taichung Veterans General Hospital/Ethics Committee for researchers who meet the criteria for access to confidential data (Tel: 886-4-23952525-4006, Fax: 886-4-23592525\#4408).

Introduction {#sec005}
============

Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness characterized by repetitive overt and covert acts which can be obsessions (i.e., intrusive recurrent thoughts), compulsions (i.e., repetitive behaviors in response to obsessions), or both \[[@pone.0162239.ref001]\]. The lifetime prevalence of OCD is 2.3% in the United States \[[@pone.0162239.ref002]\] and 0.7% in Taiwan \[[@pone.0162239.ref003]\]. Symptoms of OCD are associated with reduced quality of life \[[@pone.0162239.ref004]\] and cause significant functional impairments \[[@pone.0162239.ref005]\]. The World Health Organization has ranked OCD as one of the 10 most handicapping conditions by lost income and decreased quality of life \[[@pone.0162239.ref006]\]. Current evidence supports the use of selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacotherapy for treatment of OCD, for its' effectiveness and safety \[[@pone.0162239.ref007]\]. The U.S. food and drug administration (FDA) has approved several SSRIs such as fluoxetine, fluvoxamine, paroxetine, and sertraline for treatment of OCD.

Recently, several studies have investigated the associations between antidepressants and cerebrovascular events but the results have been inconsistent \[[@pone.0162239.ref008]--[@pone.0162239.ref017]\]. While most studies did not find an association \[[@pone.0162239.ref008],[@pone.0162239.ref009],[@pone.0162239.ref011],[@pone.0162239.ref012],[@pone.0162239.ref014],[@pone.0162239.ref016]\], more recent studies have revealed that SSRI use might be associated with increased risk of ischemic stroke \[[@pone.0162239.ref010]\], hemorrhagic stroke \[[@pone.0162239.ref015]\], or both \[[@pone.0162239.ref013], [@pone.0162239.ref017]\]. In a case-crossover study in 2011, Wu and colleagues reported increased risks of strokes among SSRI users with short-term exposure (14 days) based on a large population-based analysis in Taiwan \[[@pone.0162239.ref017]\]. More recently, Hung et al. also demonstrated increased risk of strokes among geriatric population prescribed with at least 2 months of SSRIs, using the national health insurance research database (NHIRD) in Taiwan \[[@pone.0162239.ref013]\]. However, an important methodological issue for these observational studies is that the risk of stroke among SSRI users may be confounded by indication for prescription. Besides psychiatric illness such as depression and anxiety disorders, antidepressants are widely used for treatment of various chronic and neuropathic pain disorders, such as fibromyalgia, migraine, and for reducing the pain of diabetic neuropathy \[[@pone.0162239.ref018]\]. Therefore, we do not know how much of the increase in stroke risk is attributable to the medication rather than the underlying treated diseases or other associated risk factors that distinguish users and non-users \[[@pone.0162239.ref019]\]. For example, previous studies have demonstrated that illnesses depression \[[@pone.0162239.ref020]\], panic disorder \[[@pone.0162239.ref021]\], and migraine \[[@pone.0162239.ref022]\] have an increased risk of stroke compared with the general population. Therefore, it is crucial for clinical physicians to understand the risk of stroke associated with SSRI use in each specific patient population like OCD.

However, to the best of our knowledge, there has never been any study investigating the risk of stroke in OCD patients treated with SSRIs. The National Health Insurance (NHI) program of Taiwan covers most of the population, and most medical institutions in Taiwan, and is therefore one of the largest insurance databases in the world. The NHIRD contains all claims from ambulatory and inpatient care, and has provided valuable information for a variety of epidemiological studies \[[@pone.0162239.ref023]--[@pone.0162239.ref027]\]. Therefore, the aim of this study was to examine the risk of stroke in OCD patients treated with SSRIs using the NHIRD in Taiwan.

Methods {#sec006}
=======

Data sources {#sec007}
------------

Our study was based on the patient data from NHIRD in Taiwan. The Taiwan NHIRD is a claims database maintained by the Department of Health and the National Health Research Institutes of Taiwan. The NHI program was launched in Taiwan on March 1^st^ 1995. By the end of 2010, more than 23.07 million of Taiwan's 23.16 million people were enrolled in the program \[[@pone.0162239.ref028]\]. Starting in 1999, the Bureau of NHI (NHIB) began to release all claims data in electronic format to the public under the NHIRD project. The database provides scrambled patient identification numbers, dates of birth, gender, and diagnosis in the format of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), medication prescribed, medical costs, medical care facilities, and their specialties. In the present study, the medical data for a total of 1,000,000 persons (approximately 4% of Taiwan's population), were randomly selected from the Taiwan NHIRD for the analysis. The NHIB uses a systematic sampling method to randomly extract a representative database from the entire database. There are no statistically significant differences in age, sex, and medical costs between the sample group and all other enrollees. We included medical data from individuals who were enrolled between January 1^st^, 2000, and December 31^st^, 2009, except those with questionable or inadequate basic data.

Ethics statement {#sec008}
----------------

The Institutional Review Board of Taichung Veterans General Hospital approved this study (IRB No. CE13151). NHIB released the dataset which consists of de-identified secondary data for research purposes, and therefore written consent from the study subjects was not obtained. The Institutional Review Board of Taichung Veterans General Hospital issued a formal written waiver for consent for this study.

Study design {#sec009}
------------

We conducted a retrospective observational study on the impact of SSRIs use on the incidence of stroke in patients diagnosed with OCD in Taiwan from 2001 to 2009. Patients were excluded if before 2001: 1. Ages are younger than twenty years; 2. Ever diagnosed with a stroke (ICD-9-CM codes 430.XX to 438.XX); 3. Hospitalized or received ambulatory treatment for any mental disorder (ICD-9-CM code: 290.XX-319.XX). This ensured that subsequent diagnoses of stroke and OCD were of newly onset. Study subjects were identified from 2001 to 2007 and the observation period to identify first stroke events or death extended until December 31, 2009 to ensure that study subjects could be followed for at least 3 years.

Study participants {#sec010}
------------------

New cases of OCD were ascertained by the diagnosis of ICD-9-CM code 300.3. To ensure the validity of diagnosis, at least 2 consensus OCD diagnoses after the index medical visit was required. To exclude the possible confounding effects of other psychiatric disorders, patients with any mental disorder (ICD-9-CM codes: 290.XX-319.XX) one year prior to the index medical visit for OCD diagnosis were excluded.

Definition of SSRIs exposure {#sec011}
----------------------------

In the present study, we focused on the long-term SSRI use and the incidence of stroke. Medication use was defined by receiving a prescription for a SSRI (paroxetine, fluoxetine, sertraline, citalopram, escitalopram, or fluvoxamine) for at least two consecutive months during January 1, 2001, to December 31, 2007. This criteria was the same us those adopted in our previous studies \[[@pone.0162239.ref013]\]. Patients who used only 1-month SSRI were excluded from the analysis because high possibilities of irregular SSRI use; the others were defined as non SSRI exposure group. The final sample in the study included 527 OCD patients, 412 subjects in the SSRI use group and 115 in the non SSRI use group.

Definition of incidence of stroke {#sec012}
---------------------------------

Participants were met criteria for incident stroke if they received at least two consecutive diagnoses of codes (430.XX to 438.XX) according to ICD-9-CM during the observation period after the index medical care visit for OCD.

Statistical analysis {#sec013}
--------------------

Distributions in age, gender, concomitant prescribed medications related to strokes (aspirin and Non-steroidal Anti-inflammatory Drugs \[NSAIDs\]) and comorbid medical conditions ((angina pectoris, diabetes mellitus (DM), hyperlipidemia, hypertension, atrial fibrillation, and myocardial infarction)) were examined by using χ^2^-tests. Multivariable Cox proportional-hazards models were used to explore the associations between SSRI use and risk of stroke, controlling for age, gender, concomitant medications, and medical comorbidities. All statistical tests were two sided, conducted at significance level of 0.05, and reported using *P* value and 95% confidence intervals (CIs). All analyses were performed using the SAS software, version 9.2 (SAS Institute, Cary, NC).

Results {#sec014}
=======

A total of nineteen participants had new onset of stroke during the follow-up period: six cases were in the SSRI use group and thirteen in the non SSRI use group. [Table 1](#pone.0162239.t001){ref-type="table"} compares the distribution of demographic characteristics, concomitant medications related to strokes, and relevant comorbid medical disorders between SSRI and non SSRI use groups. No instances of myocardial infarction or atrial fibrillation were observed in either group. In comparison to the SSRI use group, significantly more participants in the non SSRI use group were diagnosed with DM (*P* \< 0.05) and hypertension (*P* \< 0.02). In addition, the SSRI exposure group tended to be significantly younger than non SSRI exposure group.

10.1371/journal.pone.0162239.t001

###### Demographic and clinical characteristics of OCD subjects (n = 527).

![](pone.0162239.t001){#pone.0162239.t001g}

  Variables         Non SSRI exposure group (n = 115)   SSRI exposure group (n = 412)   *P* value for χ^2^ test           
  ----------------- ----------------------------------- ------------------------------- ------------------------- ------- ----------
  Age (year)                                                                                                              
  20--29            17                                  14.78                           121                       29.37   \<0.001
  30--39            25                                  21.74                           142                       34.47   
  40--49            27                                  23.48                           73                        17.72   
  50--59            29                                  25.22                           54                        13.11   
  60--69            9                                   7.83                            16                        3.88    
  ≥70               8                                   6.96                            6                         1.46    
  Sex                                                                                                                     
  Female            63                                  54.78                           224                       54.37   0.9372
  Male              52                                  45.22                           188                       45.63   
  Aspirin                                                                                                                 
  No                112                                 97.39                           398                       96.6    0.6718
  Yes               3                                   2.61                            14                        3.4     
  NSAID                                                                                                                   
  No                29                                  25.22                           142                       34.47   0.0611
  Yes               86                                  74.78                           270                       65.53   
  Angina Pectoris                                                                                                         
  No                114                                 99.13                           405                       98.3    0.5201
  Yes               1                                   0.87                            7                         1.7     
  DM                                                                                                                      
  No                108                                 93.91                           402                       97.57   \<0.05
  Yes               7                                   6.09                            10                        2.43    
  Hyperlipidemia                                                                                                          
  No                105                                 91.3                            388                       94.17   0.2679
  Yes               10                                  8.7                             24                        5.83    
  Hypertension                                                                                                            
  No                101                                 87.83                           388                       94.17   0.02
  Yes               14                                  12.17                           24                        5.83    
  Stroke                                                                                                                  
  No                102                                 88.7                            406                       98.54   \<0.0001
  Yes               13                                  11.3                            6                         1.46    

AP, angina pectoris; NSAID, Nonsteroidal Anti-inflammatory Drugs; DM, diabetes mellitus.

As shown in [Table 2](#pone.0162239.t002){ref-type="table"}, after adjusting for other confounding factors with multivariable Cox proportional-hazards model, SSRI use was demonstrated to be associated with a significantly decreased risk of stroke (Hazard Ratio \[HR\] = 0.30; 95% CI = 0.10--0.86, *P* = 0.02). In addition, the increase in age-related risk of strokes was 2.55 per decade (HR = 2.55; 95% CI = 1.74--3.75, *P* \< 0.001). Furthermore, sex, concomitant use of aspirin and NSAIDs, and comorbidity with angina pectoris, DM, hypertension, and hyperlipidemia did not show to increase the risk for stroke in OCD patients.

10.1371/journal.pone.0162239.t002

###### The cox proportion hazard regression model of stroke in OCD (n = 527).

![](pone.0162239.t002){#pone.0162239.t002g}

  Variable[\*](#t002fn002){ref-type="table-fn"}   Hazard Ratio   95% CI   *P* value   
  ----------------------------------------------- -------------- -------- ----------- ----------
  SSRI (Use/ Non-use)                             0.302          0.106    0.863       0.0254
  Age (every 10 years)                            2.558          1.742    3.755       \<0.0001
  Sex (Male/ Female)                              1.423          0.55     3.684       0.4668
  AP (Yes/ No)                                    2.621          0.274    25.047      0.4027
  NSAID (Yes/ No)                                 4.04           0.872    18.717      0.0743
  DM (Yes/ No)                                    2.262          0.497    10.307      0.2913
  Hypertension (Yes/ No)                          0.554          0.149    2.053       0.3765
  Hyperlipidemia (Yes/ No)                        2.384          0.626    9.082       0.2031

AP, angina pectoris; NSAID, Nonsteroidal Anti-inflammatory Drugs; DM, diabetes mellitus.

\*Due to small numbers of patients who take aspirin, it was not included in the analysis

Discussion {#sec015}
==========

To the best of our knowledge, this is the first study to investigate the risk of stroke in OCD patients treated with SSRIs. In the present study, we find SSRI use was associated with a reduced risk of stroke in OCD patients, based on a nationwide health insurance database.

OCD and risk of stroke {#sec016}
----------------------

There has been an increasing body of evidence suggesting that anxiety disorders are an independent predictor of adverse cardiovascular events. However, the evidence linking anxiety disorders and strokes are far from compelling. Moreover, there has been little research examining the physical health specifically in OCD patients until recently. Boschen and his colleagues found that in comparison to patients with other psychiatric diagnoses admitted to an acute psychiatric unit, patients OCD were more likely to have elevated serum cholesterol and serum creatinine levels \[[@pone.0162239.ref029]\]. Albert et al also found that the prevalence of the metabolic syndrome (21.2%) was higher in OCD patients compared to the general population in Italy \[[@pone.0162239.ref030]\]. These risk factors, an elevated serum creatinine \[[@pone.0162239.ref031],[@pone.0162239.ref032]\], hyperlipidemia \[[@pone.0162239.ref033]\], and the metabolic syndrome \[[@pone.0162239.ref034],[@pone.0162239.ref035]\] are known to be associated with an increased rate of strokes; it seems plausible that these risk factors should affect OCD patients to the same extent as others.

Duration of SSRIs exposure and risk of stroke {#sec017}
---------------------------------------------

Our results demonstrated that SSRI use was associated with reduced risk of stroke in OCD patients, which was inconsistent with those reported in recent studies. There are several possible explanations. First, it has been proposed that antidepressants may have acute detrimental influence but chronic beneficial effects on stroke risk \[[@pone.0162239.ref017]\]. The risks of stroke are probably higher in patient who newly uses antidepressants. Therefore, risk of stroke with antidepressant use may be varied by duration of treatment. For example, Chen and colleagues reported that antidepressant may increase risk of ischemic stroke only among current users (antidepressant within 30 days before stroke). A prospective cohort study by Smoller et al. also showed the antidepressant increased the risk of hemorrhagic stroke among new users of antidepressant \[[@pone.0162239.ref015]\]. However, it is still unclear whether the association between short-term antidepressant use and stroke is truly related to drug exposure or to acute phase of the treated underlying diseases, which might make patients more vulnerable to cardiovascular events. Second, SSRI use might express different efficacy pattern from patients of other psychiatric disorders in OCD patients. For example, Bloch et al reported the dose-response relationship of SSRI in OCD, showing that the greater side effect burden caused by higher doses of SSRI will be counterbalanced by the greater treatment efficacy \[[@pone.0162239.ref036]\], while Bollini et al showed this treatment pattern could not find in major depressive disorder (MDD) \[[@pone.0162239.ref037]\]. Therefore, discrepancies between our results and these of prior studies may be due to differences in methodology (long treatment duration) consideration and characteristics of study samples.

SSRIs use and decreased risks of stroke {#sec018}
---------------------------------------

Platelets play an important role in thrombus formation and in the repair of vascular injury \[[@pone.0162239.ref038],[@pone.0162239.ref039]\]. Serotonin concentration in platelets is crucial in maintaining the homeostatic function of platelets and the serotonin transporter (5-HTT) carrier protein functions to maintain the homeostasis of platelet serotonin concentration and serotonin level in blood \[[@pone.0162239.ref040]\]. Several weeks of treatment with a SSRI has been shown to inhibit 5-HTT and to block the reuptake of serotonin, leading to depletion of serotonin storage in platelets \[[@pone.0162239.ref041],[@pone.0162239.ref042]\]. Additionally, both *in vitro* and *ex vivo* studies showed that SSRIs decreased adenosine diphosphate (ADP) or collagen induced platelet aggregation \[[@pone.0162239.ref043],[@pone.0162239.ref044]\]. These effects may lead to attenuation of platelet activation and decrease the risk of thromboembolism formation \[[@pone.0162239.ref045]\]. This point was supported by several previous studies. In a population-based case-control analysis, Schlienger et al. provided evidence that SSRI could decrease risk for acute myocardial infarction \[[@pone.0162239.ref046]\] and several studies demonstrated no elevated risk of ischemic stroke under SSRIs use \[[@pone.0162239.ref008]\] or even some neuroprotective effect of SSRIs were reported \[[@pone.0162239.ref047]\]. Although SSRIs had the possibility of increased hemorrhage, the absolute risks between SSRI use and increases risk of hemorrhagic stroke are likely to be very low based on a meta-analysis report \[[@pone.0162239.ref048]\]. Therefore, it is plausible to consider that anti-platelet effects of SSRIs by reducing thromboemoblism could decrease the risk of strokes in OCD patients. The underlying mechanisms for the protective effects of SSRIs in OCD warrants further investigation.

Physical comorbidities and risk of stroke {#sec019}
-----------------------------------------

We did not find DM, hypertension, or hyperlipidemia associated with increased risks of stroke, which is inconsistent with previous studies \[[@pone.0162239.ref033],[@pone.0162239.ref049]\]. There are several possible explanations for this finding. First, it may suggest that OCD patients represent a special group in whom DM, hypertension, or hyperlipidemia is not associated with the risk of stroke. A population based mortality study showed that there was a lower risk of death early in life for persons with OCD, although it was higher later in life; this may be consistent with reduced health risk in OCD \[[@pone.0162239.ref050]\]. Second, it is probably due to relatively small numbers of incident cases of these physical comorbidities could be included for statistical analysis. Therefore, small numbers of cases may make the regression model un-robust, as we could see from the rather wide range of confidence intervals of these 3 diseases ([Table 2](#pone.0162239.t002){ref-type="table"}).

Strength and limitations {#sec020}
------------------------

The major strength of this study is that the findings were based on an analysis of a large sample from a nationwide population-based database, which minimized selection bias. In addition, this is the first study to investigate the SSRI-associated risk of stroke in OCD patients. However, our results should be viewed in the light of several limitations. First, relatively few incidence cases of stroke in OCD patients (n = 19) were identified, which reduces the power of this study. This was a result of the conservative definition for new-onset stroke; persons with a history of stroke prior to 2000 were excluded, i.e. recurrent episodes of stroke were excluded. In addition, we cannot examine the associations between SSRI and different types of strokes (i.e., ischemic or hemorrhagic stroke) due to limited incident cases of stroke. To solve the problem, a larger database should be used. The Taiwan NHIRD released only a random sample of the entire database for research use, preventing a larger sample size for this study. Second, OCD diagnoses, which rely on administrative claims data reported by hospitals, may be less accurate than diagnoses made according to standardized instruments (e.g., Structural Clinical Interview for DSM-IV Axis I Disorders). To ensure the validity of the diagnoses, all of the study subjects had at least two consensus OCD diagnoses after the index ambulatory care visit. In addition, the NHIB randomly samples a fixed percentage of claims from every hospital each year to ensure diagnostic validity through reviewing the symptomatologies documented in the medical records by an independent group of professional experts, and false claims would be fined \[[@pone.0162239.ref021]\]. Furthermore, some may question the accuracy of stroke-related coding in the NHIRD; however, previous studies, including one using NHIRD, have examined the validity of stroke diagnoses in claims data and showed high positive predictive values \[[@pone.0162239.ref051],[@pone.0162239.ref052]\]. Third, some important risk factors for stroke, such as cigarette smoking, alcohol consumption, obesity, and body mass index, were not available in the NHIRD. Fourth, it was not possible for us to assess medication adherence from the NHIRD. Fifth, strokes may have been diagnosed long before the registry of NHIRD was established 1995, or undiagnosed prior to the start of study; this could not be detected in, or excluded from this study. Finally, since this study was conducted in Chinese population, generalization of these findings to different populations outside Taiwan is limited.

Conclusion {#sec021}
==========

Although previous studies have found an association between cerebrovascular events and antidepressant use, we did not find an increased risk of stroke in OCD patients treated with SSRIs. Furthermore, our study showed that SSRI use was associated with decreased risk of stroke in OCD patients. Further investigation into the possible biological mechanisms underlying the relationship between stroke and antidepressants use in OCD patients is indicated.

This study is based in part on data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by National Health Research Institutes (Registered number 101095, 102148). The interpretation and conclusions contained herein do not represent those of National Health Insurance Administration, Ministry of Health and Welfare or National Health Research Institutes. Besides, the authors would like to thank the Healthcare Service Research Center (HSRC) of Taichung Veterans General Hospital for statistical support.
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